Constant investor, page-4

These are good reports (one small correction Lojsan - it's Bioshares not Biospheres just in case people are looking for it). This is the report I like best as it has a clear explanation of how things might play out. BP has been very bullish on price but the analyst does a good job of getting to know the drug development pipeline. Roth has been up there with its expectations on price for a while also. But none of them seem to be overshooting IMO. GLTA